Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II multicenter single-arm study of nilotinib in c-KIT-altered melanoma
2009-016733-10Phase 2Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nilotinib in melanoma, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: Objective response rate at 6 months and Objective response rate. Started Dec 2009; status: active.
02
Drugs
nilotinib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2009-016733-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016733-10.